Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alvocidib + cyclophosphamide + rituximab
- Development stage
- Unknown
- Lead developer
- National Cancer Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Alvocidib (flavopiridol) is a semisynthetic flavone and a potent inhibitor of cyclin-dependent kinases (CDKs), particularly CDK1, CDK2, CDK4, CDK6, and CDK9. In the CAR regimen, it is combined with the alkylating agent cyclophosphamide and the anti-CD20 monoclonal antibody rituximab. This combination was specifically investigated by the National Cancer Institute (NCI) for the treatment of high-risk B-cell chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The regimen aims to leverage the cell cycle arrest and pro-apoptotic effects of alvocidib alongside the cytotoxic effects of chemotherapy and immunotherapy, while managing risks like tumor lysis syndrome (TLS), which is a known toxicity associated with alvocidib treatment in CLL patients.
- Other names
- Alvocidib, Cyclophosphamide, and RituximabFlavopiridol, Cyclophosphamide, and RituximabCyclophosphamide, Alvocidib, and Rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)CDK1 (Cyclin-dependent kinase 1)CDK4 (Cyclin-dependent kinase 4)CDK2 (Cyclin-dependent kinase 2)CDK9 (Cyclin-dependent kinase 9)p38 mitogen-activated protein kinase (p38 MAPK)CDK6 (Cyclin-dependent kinase 6)DNA
Beyond the preview
Go deeper on alvocidib + cyclophosphamide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alvocidib + cyclophosphamide + rituximab.